TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21293245
Drug: Stereotactic radiosurgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic radiosurgery (SRS) and whole brain radiation therapy
Study: 20559273
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (treatment of glycemia, vasoactive drugs)
Study: 22281182
Drug: Miglustat 200
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Miglustat 200 mg t.i.d. for 8 days
Study: 16339692
Drug: Serum non-transferrin-bound
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum non-transferrin-bound iron (NTBI) levels measured weekly during transfusion cycles
Study: 8683231
Drug: Irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (CPT-11) at a dose of 145 mg/m2 administered as a 90-minute infusion with G-CSF and antidiarrheal support
Study: 1806467
Drug: Parlodel R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel R (conventional bromocriptine) 2.5 mg b.i.d. for 2 weeks, then doubled for 2 weeks
Study: 1806467
Drug: Parlodel SRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel SRO (slow-release bromocriptine) 5 mg once daily for 2 weeks, then doubled for 2 weeks
Study: 1806467
Drug: Parlodel SRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel SRO (slow-release bromocriptine) 2.5-10 mg daily for 6 months
Study: 25975969
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg bolus over 5 minutes, followed by 1.5 mg/kg/h continuous infusion until end of surgery)
Study: 24093844
Drug: ivabradine 7.5
Normalized name: ivabradine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 7.5 mg twice a day
Study: 16388984
Drug: CMV gB
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV gB vaccine
Study: 12804020
Drug: Algal extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algal extract in safflower oil (2 mg of astaxanthin each, 3 gelcaps per day)
Study: 10826575
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SR49059
Study: 10826575
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg SR49059
Study: 1577222
Drug: Once-a-day morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day morning administration of 40 mg famotidine
Study: 1577222
Drug: Once-a-day bedtime
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day bedtime administration of 40 mg famotidine
Study: 29706701
Drug: Spinal decompression
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal decompression therapy
Study: 15785149
Drug: Ximelagatran (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (fixed dose)
Study: 7778530
Drug: Delapril 15
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 15 mg twice daily
Study: 2318113
Drug: Threefold basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threefold basal immunosuppression (low-dose ciclosporin, azathioprine, and prednisolone)
Study: 2318113
Drug: Fourfold basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourfold basal immunosuppression (with additional poly- or monoclonal antibodies)
Study: 2318113
Drug: Additional antirejection
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional antirejection treatment with poly- or monoclonal antibodies
Study: 7350888
Drug: Electronic intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic intravenous (IV) rate controller
Study: 31915038
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet and resistance training combination
Study: 27458993
Drug: Artesunate combination
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate combination therapy (ACT)
Study: 21558397
Drug: Topical CUR61414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical CUR61414 in preclinical studies
Study: 19465442
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (500 microg twice daily from a Diskus inhaler)
Study: 19465442
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (30 mg daily)
Study: 15202770
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral lorazepam (0.5 mg or 1 mg)
Study: 9537307
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of bombesin (0.09 nmol/kg ideal weight/h)
Study: 2225536
Drug: 0.1% betamethasone‐17‐valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone‐17‐valerate cream (Betnovate)
Study: 2225536
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol proprionate cream (Dermovate)
Study: 2225536
Drug: base cream
Normalized name: U-Base Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: base cream
Study: 29122156
Drug: Reslizumab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab 3.0 mg/kg intravenously every 4 weeks for up to 24 months
Study: 25744962
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) plus Healthy Lifestyles intervention
Study: 25744962
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) plus predominantly telephone-based intervention
Study: 23512860
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention (ILI) on statin therapy
Study: 23512860
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care on statin therapy
Study: 23512860
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention (ILI) not on statin therapy
Study: 19704175
Drug: TMC278 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 25 mg
Study: 19704175
Drug: TMC278 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 50 mg
Study: 19704175
Drug: TMC278 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 150 mg
Study: 13129464
Drug: FOS-supplemented infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS-supplemented infant cereal (0.75 g FOS per serving)
Study: 6347749
Drug: Ketotifen (0.5-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (0.5-1 mg b.i.d. for 12 weeks)
Study: 2582325
Drug: Intensive cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cyclic therapy using either the same drugs of the induction regimen or rotating combinations of alternative drugs (e.g., mAMSA, 5-AZA, HD-Ara C)
Study: 23753021
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment
Study: 2582325
Drug: Induction or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction or maintenance treatment
Study: 29190004
Drug: Tailored dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A)
Study: 29190004
Drug: Fixed doses
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed doses of the same regimen (group B)
Study: 18199863
Drug: Etanercept (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (0.8 mg/kg, max 50 mg)
Study: 18199863
Drug: Etanercept (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (after 24 weeks of open-label treatment)
Study: 18199863
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after 24 weeks of open-label treatment)
Study: 18199863
Drug: Etanercept (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (open-label treatment)
Study: 12575908
Drug: Whey preload
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey preload (48 g, 1700 kJ liquid preload)
Study: 10232292
Drug: Active catecholamine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active catecholamine depletion via oral administration of 5 g alpha‐methylparatyrosine
Study: 10232292
Drug: Sham catecholamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham catecholamine depletion via oral administration of 250 mg diphenhydramine hydrochloride
Study: 8734351
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (1000 mg)
Study: 27112475
Drug: Arterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arterial infusion with 8 ml of 1% methylene blue
Study: 27112475
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without artery infusion
Study: 22627477
Drug: PF‐04523655 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04523655 (50 to 3000 μg)
Study: 19067709
Drug: Two-compound scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound scalp formulation (calcipotriol 50 microg g(‐1) plus betamethasone 0.5 mg g(‐1))
Study: 19067709
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.5 mg g(‐1)
Study: 19067709
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg g(‐1)
Study: 17976797
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol ingested 1.5 h before oxycodone
Study: 17976797
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg immediate-release oxycodone orally
Study: 12593694
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g intravenously before operation and 1 g intravenously at the end of cardiopulmonary bypass (Group 1)
Study: 12593694
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g intravenously before operation, followed by continuous intravenous infusion at 20 mg/min throughout surgery (Group 2)
Study: 12593694
Drug: Cefazolin 3
Normalized name: cefazolin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 3 g intravenously before operation, followed by continuous intravenous infusion at 15 mg/min throughout surgery (Group 3)
Study: 10491209
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D receptor genotype (TaqI, ApaI)
Study: 10491209
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D receptor polymorphisms (TaqI and ApaI)
Study: 8708714
Drug: Diethylstilbestrol (DES,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES, 1 mg three times daily)
Study: 6293321
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen producing less depression and fatigue
Study: 6293321
Drug: Other chemotherapy
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other chemotherapy regimen
Study: 12185396
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg daily
Study: 8118471
Drug: Citalopram 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 60 mg daily
Study: 12185396
Drug: Citalopram 10
Normalized name: citalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10 mg daily
Study: 12185396
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg daily
Study: 12185396
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg and 60 mg daily
Study: 30652031
Drug: Combined genotypes
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined genotypes ProAla + AlaAla and GC + CC
Study: 27835716
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment for 8 weeks
Study: 27835716
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment for patients with objective memory dysfunction at baseline (n = 16)
Study: 21847713
Drug: 0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/day RPM
Study: 21847713
Drug: 2.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/day RPM
Study: 21847713
Drug: 3.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g/day RPM
Study: 21847713
Drug: 4.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g/day RPM
Study: 20303474
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg single oral dose of D-cycloserine (DCS)
Study: 7894879
Drug: Amisulpride 100
Normalized name: amisulpride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 100 mg/d
Study: 7894879
Drug: Amisulpride 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 300 mg/d
Study: 2484467
Drug: MSD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSD vaccine (2 doses)
Study: 2484467
Drug: Pasteur vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasteur vaccine (3 doses)
Study: 25486932
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence information (AI) provided to physician
Study: 25486932
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence information (AI) and motivational interviewing (MI)
Study: 23023528
Drug: Fenretinide 300
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide 300 mg daily
Study: 23023528
Drug: Fenretinide 100
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide 100 mg daily
Study: 15710069
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day + UDCA 300 mg/day
Study: 15710069
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day + UDCA 300 mg/day
Study: 11098961
Drug: Hypocaloric feeding
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric feeding (1 L containing 70 g protein and 1000 kcal)
Study: 11098961
Drug: Standard weight‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight‐based regimen (25 kcal and 1.5 g protein/kg dry weight)
Study: 8159594
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine in chocolate wafer
Study: 8159594
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine mixed with Isocal
Study: 2851016
Drug: Enoxaparine 60
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparine 60 mg
Study: 2851016
Drug: Enoxaparine 80
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparine 80 mg
Study: 28324706
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (40IU) with positive emotion inductions
Study: 27367855
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg Se as selenized yeast) and Coenzyme Q10 (200 mg) supplementation for four years
Study: 19277942
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration (WBV) training, 30 Hz, 4 mm amplitude, thrice weekly for 3 min for 4 weeks
Study: 7959554
Drug: Preoperative course
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative course of chemotherapy and radiotherapy
Study: 2954497
Drug: Clemastine 1
Normalized name: clemastine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 1 mg twice daily
Study: 31678343
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day vortioxetine
Study: 31678343
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day vortioxetine
Study: 31678343
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day escitalopram
Study: 27720136
Drug: Sunitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib plus IMA901 (4·13 mg) and granulocyte macrophage colony-stimulating factor (75 μg), with cyclophosphamide (300 mg/m2) 3 days before the first vaccination.
Study: 27720136
Drug: Sunitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib monotherapy (50 mg orally once daily).
Study: 24925120
Drug: Full-dose nuts
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose nuts (50-100 g/d)
Study: 24925120
Drug: Half-dose nuts
Normalized name: Half Beta-Prograne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose nuts with half-dose muffins
Study: 24925120
Drug: Full-dose nuts
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose nuts
Study: 19076630
Drug: Efalizumab, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab, 1 mg/kg/week administered subcutaneously for up to 15 months
Study: 16189176
Drug: GH and
Normalized name: Cough And Cold
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH and acipimox co-administration
Study: 16189176
Drug: Acipimox administration
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox administration
Study: 14624289
Drug: Nimesulide 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 300 mg
Study: 10951149
Drug: Mite allergen
Normalized name: house dust mite allergen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mite allergen avoidance measures (encasing mattresses and pillows; weekly hot wash of bedding; frequent vacuum cleaning; cleaning/removing soft toys and carpets; no pets allowed)
Study: 10160375
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment (five doses in Sierra Leone, three doses in Nigeria)
Study: 8296531
Drug: L-threonine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine at 6 g/day
Study: 3711553
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) aqueous spray, 42 mcg per spray
Study: 3711553
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) aerosol spray, 42 mcg per spray
Study: 29713137
Drug: Parent Child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent Child Interaction Therapy (individualized mastery‐based coaching; PCIT)
Study: 19884812
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy (daily local mud packs and bicarbonate-sulfate mineral bath water) for 2 weeks
Study: 10807894
Drug: L/MCT diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/MCT diet (equal quantities of LCT and MCT)
Study: 8862439
Drug: 10, 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 25, 50, or 75 micrograms/kg/day of rhIL-11 administered subcutaneously for 14 consecutive days
Study: 8862439
Drug: rhIL-11 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 treatment at the two highest doses
Study: 8862439
Drug: rhIL-11 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 treatment
Study: 8862439
Drug: rhIL-11 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 therapy at the highest dose
Study: 8862439
Drug: rhIL-11 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 administration
Study: 4091995
Drug: Meptazinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (200 mg)
Study: 4091995
Drug: Dextropropoxyphene/paracetamol mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg)
Study: 4091995
Drug: Dextropropoxyphene/paracetamol mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg) + Ethanol (0.8 g kg‐1)
Study: 4091995
Drug: Ethanol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.8 g kg‐1)
Study: 4091995
Drug: Meptazinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (200 mg) + Ethanol (0.8 g kg‐1)
Study: 18815396
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (0.9 mg per kilogram of body weight)
Study: 12607792
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg (for patients weighing <= 30 kg)
Study: 12607792
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg (for patients weighing > 30 kg)